MAPS Public Benefit Corporation (MAPS PBC) welcomes Jason Pyle, an experienced CEO and executive leader, to their Board of Directors. A wholly-owned subsidiary of the Multidisciplinary Association of Psychedelic Studies (MAPS), MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. This addition will expand the Board of Directors to six individuals who together hold several decades of combined experience in business, finance, and pharmaceutical development.
“The impact MDMA promises to have on PTSD is truly game changing. It’s very exciting to join MAPS PBC’s dedicated and talented team and be a part of this historic effort.”
Mr. Pyle has deep leadership experience developing and growing innovation-driven companies with over 15 years of executive leadership in the management of IP portfolios, global business, business model repositioning, operational initiatives, and the building of high-performing, high-executing teams. He is highly accomplished at integrating varied corporate stakeholder groups, including the investment community, with a focus on high-impact results in today’s changing and increasingly connected global technology economies.
Bringing all of this to bear at MAPS PBC, Jason adds value to a quickly-growing and ever-evolving organization through a period of rapid expansion. As commercialization of MDMA for psychedelic-assisted therapy draws ever-nearer, Jason will help guide MAPS PBC towards psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit.
Amy Emerson Named Chief Executive Officer
Under the leadership of Amy Emerson, who has been at the helm of MAPS PBC since its formation and was recently named Chief Executive Officer, the public benefit corporation is conducting the worlds’ first and largest MDMA-assisted therapy clinical trials. More than a dozen trial sites in the United States, the Czech Republic, Portugal, the Netherlands, and Israel will be conducting therapy according to the protocols developed and published by MAPS PBC, with initial results from the first stage of the study expected this winter.
Following MAPS PBC’s recent announcement of the publication of the long-term follow-up results of six Phase 2 clinical trials of MDMA-assisted therapy for the treatment of posttraumatic stress disorder (PTSD) in the peer-reviewed journal Psychopharmacology, the addition of Mr. Pyle to the Board signifies the growth MAPS PBC is undertaking as it advances toward the unprecedented legal approval of psychedelic-assisted therapy to help address the mental health epidemic gripping the world.
The safety and efficacy of MDMA-assisted therapy is currently under investigation. It has not yet been approved by the FDA, does not work for everyone, and carries risks even in therapeutic settings. These statements are no guarantee of future FDA approval or availability of MDMA-assisted therapy. These statements necessarily involve known and unknown risks and uncertainties, which may cause actual outcomes to differ materially from our projections.